Last $146.72 USD
Change Today -1.82 / -1.23%
Volume 1.2M
BDX On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 4:15 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

becton dickinson and co (BDX) Snapshot

Open
$148.90
Previous Close
$148.54
Day High
$148.90
Day Low
$146.47
52 Week High
02/24/15 - $149.14
52 Week Low
05/1/14 - $111.07
Market Cap
28.3B
Average Volume 10 Days
1.1M
EPS TTM
$6.16
Shares Outstanding
192.9M
EX-Date
03/6/15
P/E TM
23.8x
Dividend
$2.40
Dividend Yield
1.52%
Current Stock Chart for BECTON DICKINSON AND CO (BDX)

becton dickinson and co (BDX) Related Businessweek News

View More BusinessWeek News

becton dickinson and co (BDX) Details

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company’s BD Medical segment produces medical devices, such as needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for use in the treatment of diabetes; prefillable drug delivery systems; anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; and generic prefilled injectables. Its BD Diagnostics segment provides products for the collection and transportation of diagnostics specimens; and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections, and cancers. This segment’s products include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood and tuberculosis culturing systems; molecular testing systems; microorganism identification and drug susceptibility systems; liquid-based cytology systems; rapid diagnostic assays; microbiology laboratory automation; and plated media. The company’s BD Medical segment offers research and clinical tools, such as fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. It also develops technologies that address biological analysis protocols, including library preparation of next generation sequencing and genotyping applications. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

30,619 Employees
Last Reported Date: 11/26/14
Founded in 1897

becton dickinson and co (BDX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $985.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $690.2K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $721.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $900.8K
Executive Vice President
Total Annual Compensation: $605.7K
Compensation as of Fiscal Year 2014.

becton dickinson and co (BDX) Key Developments

Becton, Dickinson and Company Announces Consolidated Unaudited Earnings Results for the First Quarter Ended December 31, 2014; Provides Earnings Guidance for the Full Year of Fiscal 2015

Becton, Dickinson and Company announced consolidated unaudited earnings results for the first quarter ended December 31, 2014. For the quarter, the company reported revenues of $2,051 million compared with $2,015 million for the same period a year ago. Operating income was $349 million compared with $378 million for the same period a year ago. Income before tax was $236 million compared with $271 million for the same period a year ago. Net income was $236 million or $1.20 per diluted share compared with $271 million or $1.37 per diluted share for the same period a year ago. Adjusted diluted earnings per share was $1.53 compared with $1.43 for the same period a year ago. The company estimates that revenues for the full fiscal year 2015 will increase approximately 5.0% on a foreign currency-neutral basis, which is an increase from previously issued guidance of 4.5% to 5%. On a reported basis, revenues are expected to be about flat to a decline of 1.0%, due to the unfavorable impact of foreign currency. The company expects adjusted diluted earnings per share from continuing operations to grow 9.0% to 10.0% on a foreign currency-neutral basis. This is an increase from previously issued guidance of 8.0% to 9.0%. Including the estimated unfavorable impact of foreign-currency, adjusted diluted earnings per share are expected to be between $6.50 and $6.57. Adjusted diluted earnings per share for the full fiscal year 2014 were $6.50. The company expects full fiscal year reported diluted earnings per share from continuing operations to be between $5.98 to $6.05.

Becton, Dickinson and Company Declares Quarterly Cash Dividend, Payable on March 31, 2015

The Board of Directors of Becton, Dickinson and Company declared a quarterly dividend of 60 cents per common share, payable on March 31, 2015 to holders of record on March 10, 2015. The indicated annual dividend rate is $2.40 per share.

Becton, Dickinson and Company - Shareholder/Analyst Call

Annual Meeting of Shareholders

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BDX:US $146.72 USD -1.82

BDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $42.21 USD -0.15
Astellas Pharma Inc ¥1,901 JPY +3.00
Illumina Inc $195.46 USD -3.00
Mylan Inc/PA $57.33 USD +0.08
Zimmer Holdings Inc $120.39 USD -0.94
View Industry Companies
 

Industry Analysis

BDX

Industry Average

Valuation BDX Industry Range
Price/Earnings 25.5x
Price/Sales 3.4x
Price/Book 5.7x
Price/Cash Flow 24.9x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BECTON DICKINSON AND CO, please visit www.bd.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.